Case builds for mixing COVID-19 vaccine doses

It looks promising, but the evidence is not there yet, expert says
Associate Professor Paul Griffin
Associate Professor Paul Griffin.

Australia will eventually move to a heterologous COVID-19 vaccination regimen if the evidence firms up, a leading infectious diseases specialist predicts.

Associate Professor Paul Griffin has responded to the weekend news that Canadian health authorities have recommended people who have received a first dose of AstraZeneca’s vaccine should have an mRNA shot as their second dose.